Considering Treatment Options in Advanced
Non-Small Cell Lung Cancer

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive of the live session held at the 2010 Spring Managed Care Forum. If you participated in the live activity, you are not eligible for continuing education credits from this archive.

This activity is valid from July 18, 2011 to July 18, 2012
These presentations require Internet Explorer 5.0 or later, Netscape Navigator 7.0 or later, or Internet Explorer 5.2.2 for Mac.  To Download the latest version of Internet Explorer from the Microsoft web site, click here.

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from Genentech BioOncology/OSI Oncology
 
PLEASE CLICK HERE TO VIEW THE PRESENTATION

 PLEASE CLICK HERE FOR POST TEST AND EVALUATION

Instructions for CME/CEU: Read the article, answer the post test, complete the evaluation form, and hit submit. A score of 70% must be achieved on the post test to receive continuing education credits. You will have the option on the post test/evaluation page to submit your forms electronically or you can fax them to Katie Eads at 804-747-5316.

Description
Lung cancer is the second most common cancer in both men and women, according to the American Cancer Society. It accounts for about 15% of all new cancers, and during 2010, it is expected that there will be about 219,440 new cases of lung cancer. Non small-cell lung cancer (NSCLC) accounts for approximately 15% of all lung cancer cases. Lung cancer is by far the leading cause of cancer death among both men and women, and there will be an estimated 159,000 deaths from lung cancer in 2010, accounting for around 29% of all cancer deaths. More people die of lung cancer than of colon, breast, and prostate cancers combined. However, advances in our knowledge of cancer cell biology have led to the development of specific molecular-targeted therapeutic agents, offering oncologists more treatment options in the fight against NSCLC.

Upon Completion of this activity, participants will be able to:

  • Describe the epidemiology, risk factors, and pathology of lung cancer

  • Identify current treatment standards for NSCLC

  • Discuss the evolving role of targeted agents and molecular selection in treatment of NSCLC

  • Review current guidelines for the treatment of advanced NSCLC

Faculty: Tom Stinchcombe, MD
Division of Hematology and Oncology
UNC Lineberg Comprehensive Cancer Center

Disclosure:

 Dr. Stinchcombe serves on the speakers bureau for Lilly and Genentech and has received research funding for clinical trials from Abraxis Bioscience, Bayer and Genentech.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses (AAMCN) has been approved as a provider of continuing education by the Virginia Nurses Association (VNA). VNA is accredited as an approver of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation. Nurses who complete this activity will be awarded 1.0 contact hours.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.
   

This activity is supported by an educational grant from Genentech BioOncology/OSI Oncology
 

NAMCP and or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.